CTX-009

DRUG4 trials

Conditions

Ampullary CancerBiliary Tract CancerCholangiocarcinomaColon CancerGall Bladder CancerGlioblastomaMetastatic Biliary Tract CancerMetastatic Colorectal Cancer

Phase 1

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

RecruitingNCT06548412

M.D. Anderson Cancer CenterMetastatic Biliary Tract Cancer

Start: 2025-01-22End: 2029-05-01Target: 50Updated: 2026-09-09

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

RecruitingNCT07392957

Washington University School of MedicineGlioblastoma

Start: 2026-06-16End: 2031-06-30Target: 54Updated: 2026-06-22

Phase 2

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Active, not recruitingNCT05506943

Compass TherapeuticsAmpullary Cancer, Biliary Tract Cancer, Cholangiocarcinoma +1

Start: 2023-01-09End: 2027-08-31Updated: 2026-09-02

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

CompletedNCT05513742

Compass TherapeuticsColon Cancer, Metastatic Colorectal Cancer, Rectal Cancer

Start: 2022-12-08End: 2025-05-15Updated: 2026-07-28

Related Papers

Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003).

Journal of Clinical Oncology2026-01-10

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC

Future Oncology2024-06-042 citations

Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.

Journal of Clinical Oncology2023-01-241 citations

Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens.